Mereo BioPharma Group plc

Earnings Release • Jun 27, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2991J

Mereo BioPharma Group plc

27 June 2017

Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

Result of Annual General Meeting

London, 27 June 2017 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.

For Further Enquiries:

Mereo BioPharma Group plc	+44 (0)333 023 7319
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer
Nominated Adviser and Joint Broker Cantor Fitzgerald Europe	+44 (0)20 7894 7000
Phil Davies
Will Goode
Joint Broker RBC Capital Markets	+44 (0)20 7653 4000
Rupert Walford
Laura White
Public Relations Adviser to Mereo Biopharma FTI Consulting	+44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard

About Mereo

Mereo BioPharma is an innovative biopharma company established to address the R&D and financial challenges faced by an increasing number of large pharma and biotech companies. Mereo focuses on developing and optimizing the value of novel medicines acquired from large pharma and biotech designed to address significant unmet medical needs in rare and specialty disease areas.

Mereo is comprised of a strong team with broad operational capabilities and the financial resources to conduct comprehensive clinical studies. The Company plans to build a rare and orphan commercial business combined with plans to partner where relevant.

Mereo's initial portfolio consists of three mid-late stage clinical assets that were acquired from Novartis in July 2015 each with proof of concept data in the indication that Mereo is now developing.  BPS-804 is being developed for the prevention of fractures resulting from osteogenesis imperfecta (brittle bone disease); acumapimod (BCT-197), is being developed to treat inflammation in patients with an AECOPD; and BGS-649 is a once-weekly oral novel therapy that restores the patient's own testosterone in men with hypogonadotropic hypogonadism.

In H1 2016 the Company initiated a Phase 2 study with acumapimod and a Phase 2b study with BGS-649. Mereo recently announced commencement of the first pivotal trial for BPS-804 and completion of enrolment of the Acumapimod Phase 2 study. Additional product opportunities, from a range of large pharmaceutical and biotechnology companies, are under active evaluation.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGOKODBKBKDDAB